Adaptive Biotechnologies Rises 10% As Revenue Surges Over 50%

Adaptive Biotechnologies reported preliminary, unaudited Q4 2025 revenue of $72.0M (MRD revenue ~$62M) versus $47.5M ($40.1M MRD) in Q4 2024, and full-year 2025 revenue of ~$277M (MRD $212M) versus $179.0M (MRD $145.5M) in 2024. clonoSEQ test volume rose to 30,000 tests in Q4 2025 (+43% y/y) and ~105,600 tests for the year (+39% y/y), underpinning MRD growth; the stock rallied over 10% premarket to $17 on the print. Management will release complete audited results in February 2026, leaving room for detail-driven market reactions ahead of the full report.

Analysis

Market structure: Adaptive (ADPT) is the clear near-term beneficiary — MRD revenue of $212M and 39% test-volume growth (105.6k tests) in 2025 implies accelerating adoption and scope for scale-driven margin expansion. Labs that process samples, NGS reagent suppliers and specialist oncology centers also benefit; incumbent broad oncology diagnostics (e.g., Guardant Health GH, Exact Sciences EXAS) face competitive pressure for MRD dollars in hematologic indications but aren't direct one-to-one displacers yet. Faster-than-expected volume growth strengthens ADPT’s negotiating leverage with payers for per-test pricing and coverage contracts over the next 6–24 months.

Risk assessment: Key tail risks are regulatory/reimbursement reversal (FDA label changes or CMS/NCD limits), operational capacity constraints (lab throughput/reagent shortages), and IM-program clinical failures that could re-rate valuation — each could knock 30–70% of near-term upside in stressed scenarios. Timeframes: immediate (days) — sentiment-driven volatility around preliminary print; short-term (weeks–months) — full FY results in Feb 2026 and payer negotiations; long-term (quarters–years) — clinical validation/IM therapeutics determining optionality value. Hidden dependencies include concentration of large oncology customers and third-party lab logistics; a lost major payer contract would materially compress revenue growth.

Trade implications: Tactical: establish a modest 2–3% long ADPT position at current $16–17 to capture momentum into Feb results, layering add-on to 4–5% if price retraces to $12–14 (risk-reward >2:1). Use a 3–6 month call spread to express upside with limited capital (buy Jun 2026 $15 call, sell Jun 2026 $25 call) and hedge with a cheap put spread (buy Jun 2026 $12 put, sell Jun 2026 $8 put) to limit downside. Relative value: consider long ADPT / short GH sized to be beta-neutral (6–12 month horizon) to isolate diagnostics vs broader liquid tumor MRD exposure.

Contrarian angles: The market may be underpricing the IM pipeline optionality — if Adaptive secures one strategic partnership or positive Phase signal in 12–18 months, upside could re-rate >2x current market cap; conversely the premarket pop may be overdone given full financials are unaudited and Feb release is a binary catalyst. Historical parallels: diagnostic winners often see volatile re-rating around initial payer coverage windows (e.g., Guardant post-CMS decisions); outcome-dependent moves can be swift and large, so size positions with explicit stop-loss/tranch rules.

Key Decisions for Investors

• Initiate a 2–3% long position in ADPT (ticker ADPT) at market ($16–17) ahead of Feb 2026 full results; if ADPT retreats to $12–14, scale to a total 4–5% position. Rationale: 39–43% volume growth and $212M MRD revenue imply durable top-line momentum; target 6–12 month hold, sell into strength >50% from entry or if Feb results miss.
• Execute a defined-risk options combo: buy Jun 2026 $15 calls and sell Jun 2026 $25 calls (ratio size to equity stake) to cap cost, and buy Jun 2026 $12 puts / sell Jun 2026 $8 puts as a protective put spread. This preserves upside while limiting max loss to the put-spread width plus net premium.
• Run a pair trade: long ADPT vs short Guardant Health (GH) to neutralize broader market/NGS volatility — size to be beta-neutral with a 6–12 month horizon. Close or rebalance if ADPT/GH spread widens >30% or upon decisive payer/CMS rulings.
• Trigger-based action: if CMS or a top-3 national private payer grants explicit favorable MRD coverage within 30–90 days, increase ADPT exposure by another 2–3%; conversely, if any adverse reimbursement guidance or FDA concern appears, reduce ADPT weight by at least 50% immediately.